Skip to main content

PAPEL DEL ADAPTADOR FADD EN LA SEÑALIZACION DE RECEPTORES 7TM Y DE CANALES IONICOS ACTIVADOS POR LIGANDO: ENFOQUES FARMACOLOGICOS, CONDUCTUALES Y FISIOPATOLOGICOS

SAF2011-29918

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2011
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSIDAD DE LAS ISLAS BALEARES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: the role of platelet IRAS/Nischarin (I1-Imidazoline Receptor)

  • Keller, Benjamin
  • Mestre-Pintó, Juan Ignacio
  • Álvaro-Bartolomé, María
  • Martínez-Sanvisens, Diana
  • Farré Albaladejo, Magí
  • García-Fuster, M. Julia
  • García Sevilla, Jesús
  • Torrens, Marta
  • The NEURODEP Group
The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD- comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology., The study was supported by grants SAF2011-29918 (JAG-S) and SAF2014-55903-R (MJG-F) from Ministerio de Economía y Competitividad (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) and by grants PS09/02121 and PI12/01838 (MT) from Instituto de Salud Carlos III (ISCIII) and FIS-FEDER, Madrid, Spain. The research was also funded by Redes Temáticas de Investigación Cooperativa en Salud–Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011, RD12/0028/0009, RD16/0017/0003, and RD16/0017/0010) (ISCIII and FEDER), Madrid, Spain. This work was also supported by grants 2012/011 and 2016/002 (MJG-F) from Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain. BK was supported by a predoctoral contract from RETICS-RTA. MJG-F is a “Ramón y Cajal” Researcher (MINECO-UIB). JG-S is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain). We are grateful to Esther Menoyo, Marta Pérez, Soraya Martín, and Clara Gibert for their valuable assistance throughout the clinical part of the study.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of Gαi2 and Gαz protein knockdown on alpha2A-adrenergic and cannabinoid CB1 receptor regulation of MEK-ERK and FADD pathways in mouse cerebral cortex

  • Ramos-Miguel, A.
  • Sánchez-Blázquez, Pilar
  • García-Sevilla, Jesús Andrés
Background: Alpha-adrenergic (α-AR) and cannabinoid CB (CB-R) receptors exert their functions modulating multiple signaling pathways, including MEK-ERK (extracellular signal-regulated kinases) and FADD (Fas-associated protein with death domain) cascades. These molecules are relevant in finding biased agonists with fewer side effects, but the mechanisms involving their modulations by α-AR- and CB-R in vivo are unclear. This study investigated the roles of Gαi and Gαz proteins in mediating α-AR- and CB-R-induced alterations of MEK-ERK and FADD phosphorylation (p-) in mouse brain cortex. Methods: Gαi or Gαz protein knockdown was induced in mice with selective antisense oligodeoxinucleotides (ODNs; 3 nmol/day, 5 days) prior to UK-14,304 (UK or brimonidine; 1 mg/kg) or WIN55212-2 (WIN; 8 mg/kg) acute treatments. Inactivated (p-T) MEK1, activated (p-S) MEK1/2, activated (p-T/Y) ERK1/2, p-S FADD, and the corresponding total forms of these proteins were quantified by immunoblotting. Results: Increased (+ 88%) p-T MEK1 cortical density, with a concomitant reduction (–43%) of activated ERK was observed in UK-treated mice. Both effects were attenuated by Gαi or Gαz antisense ODNs. Contrastingly, WIN induced Gαi- and Gαz-independent upregulations of p-T MEK1 (+ 63%), p-S MEK1/2 (+ 86%), and activated ERK (+ 111%) in brain. Pro-apoptotic FADD was downregulated (− 34 to 39%) following UK and WIN administration, whereas the neuroprotective p-S FADD was increased (+ 74%) in WIN-treated mice only. None of these latter effects required from Gαi or Gαz protein integrity. Conclusion: The results indicate that α-AR (UK), but not CB-R (WIN), agonists use Gαi and Gαz proteins to modulate MEK-ERK, but not FADD, pathway in mouse brain cortex., The study was supported by grants RTI2018-094414-A-I00 (AR-M), SAF2011-29918 (JAG-S), and RT 2018-093677-B-100 (PSB) from the Spanish Ministry of Science, Innovation and Universities (MCIU) and the European Regional Development Fund (ERDF). AR-M is a ‘Ramón y Cajal’ Researcher (grant RYC-2016-19282) supported by MCIU. JAG-S is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain). None of the above funding agencies took part in the elaboration of the study, formulation of the hypotheses, or interpretation of the results.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Effects of Gαi2 and Gαz protein knockdown on alpha2A-adrenergic and cannabinoid CB1 receptor regulation of MEK-ERK and FADD pathways in mouse cerebral cortex

  • Robles-Ramos, Miguel A.
  • Sánchez-Blázquez, Pilar
  • García-Sevilla, Jesús Andrés
Background: Alpha-adrenergic (α-AR) and cannabinoid CB (CB-R) receptors exert their functions modulating multiple signaling pathways, including MEK-ERK (extracellular signal-regulated kinases) and FADD (Fas-associated protein with death domain) cascades. These molecules are relevant in finding biased agonists with fewer side effects, but the mechanisms involving their modulations by α-AR- and CB-R in vivo are unclear. This study investigated the roles of Gαi and Gαz proteins in mediating α-AR- and CB-R-induced alterations of MEK-ERK and FADD phosphorylation (p-) in mouse brain cortex. Methods: Gαi or Gαz protein knockdown was induced in mice with selective antisense oligodeoxinucleotides (ODNs; 3 nmol/day, 5 days) prior to UK-14,304 (UK or brimonidine; 1 mg/kg) or WIN55212-2 (WIN; 8 mg/kg) acute treatments. Inactivated (p-T) MEK1, activated (p-S) MEK1/2, activated (p-T/Y) ERK1/2, p-S FADD, and the corresponding total forms of these proteins were quantified by immunoblotting. Results: Increased (+ 88%) p-T MEK1 cortical density, with a concomitant reduction (–43%) of activated ERK was observed in UK-treated mice. Both effects were attenuated by Gαi or Gαz antisense ODNs. Contrastingly, WIN induced Gαi- and Gαz-independent upregulations of p-T MEK1 (+ 63%), p-S MEK1/2 (+ 86%), and activated ERK (+ 111%) in brain. Pro-apoptotic FADD was downregulated (− 34 to 39%) following UK and WIN administration, whereas the neuroprotective p-S FADD was increased (+ 74%) in WIN-treated mice only. None of these latter effects required from Gαi or Gαz protein integrity. Conclusion: The results indicate that α-AR (UK), but not CB-R (WIN), agonists use Gαi and Gαz proteins to modulate MEK-ERK, but not FADD, pathway in mouse brain cortex., The study was supported by grants RTI2018-094414-A-I00 (AR-M), SAF2011-29918 (JAG-S), and RT 2018-093677-B-100 (PSB) from the Spanish Ministry of Science, Innovation and Universities (MCIU) and the European Regional Development Fund (ERDF). AR-M is a ‘Ramón y Cajal’ Researcher (grant RYC-2016-19282) supported by MCIU. JAG-S is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain). None of the above funding agencies took part in the elaboration of the study, formulation of the hypotheses, or interpretation of the results.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A biomarker to differentiate between primary and cocaine-induced major depression in cocaine use disorder: the role of platelet IRAS/Nischarin (I1-Imidazoline Receptor)

  • Keller, Benjamin
  • Mestre-Pintó, Juan Ignacio
  • Álvaro-Bartolomé, María
  • Martínez-Sanvisens, Diana
  • Farré Albaladejo, Magí
  • García-Fuster, M. Julia
  • García Sevilla, Jesús
  • Torrens, Marta
  • The NEURODEP Group
The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD- comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology., The study was supported by grants SAF2011-29918 (JAG-S) and SAF2014-55903-R (MJG-F) from Ministerio de Economía y Competitividad (MINECO) and Fondo Europeo de Desarrollo Regional (FEDER) and by grants PS09/02121 and PI12/01838 (MT) from Instituto de Salud Carlos III (ISCIII) and FIS-FEDER, Madrid, Spain. The research was also funded by Redes Temáticas de Investigación Cooperativa en Salud–Red de Trastornos Adictivos (RETICS-RTA, RD12/0028/0011, RD12/0028/0009, RD16/0017/0003, and RD16/0017/0010) (ISCIII and FEDER), Madrid, Spain. This work was also supported by grants 2012/011 and 2016/002 (MJG-F) from Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain. BK was supported by a predoctoral contract from RETICS-RTA. MJG-F is a “Ramón y Cajal” Researcher (MINECO-UIB). JG-S is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain). We are grateful to Esther Menoyo, Marta Pérez, Soraya Martín, and Clara Gibert for their valuable assistance throughout the clinical part of the study.